Press Release: Roche : Roche provides update on Phase III OCREVUS high dose study in people with relapsing multiple sclerosis

MUSETTE trial was designed to determine whether a higher dose of the currently approved OCREVUS IV 600 mg would provide additional benefit to people living with relapsing...